Inventor · disambiguated record
James A. Henderson
Also filed as: HENDERSON JAMES · HENDERSON JAMES A
24 granted patents·19 pending applications·262 citations·filing 2010–2024
96Inventor score
Top patents by PatentIndex Score
43 records- 0197US11407732B1Tricyclic degraders of Ikaros and AiolosC4 THERAPEUTICS INC·Filed 2021·Granted Aug 9, 2022·10 cites·30 claims
- 0297US11185592B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Nov 30, 2021·20 cites·26 claims
- 0397US10660968B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·32 cites·35 claims
- 0496US11524949B2Degraders and Degrons for targeted protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Dec 13, 2022·7 cites·18 claims
- 0596US10905768B1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Feb 2, 2021·31 cites·20 claims
- 0696US10849982B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted Dec 1, 2020·43 cites·17 claims
- 0796US10646575B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 12, 2020·32 cites·28 claims
- 0895US12048747B2Substituted piperidine Degronimers for Target Protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Jul 30, 2024·4 cites·22 claims
- 0994US11459335B2N/O-linked Degrons and Degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·8 cites·23 claims
- 1093US11992531B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted May 28, 2024·3 cites·31 claims
- 1193US8466288B2Isoindolinone inhibitors of phosphatidylinositol 3-kinaseARONOV ALEX·Filed 2012·Granted Jun 18, 2013·38 cites·18 claims
- 1290US12048748B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Jul 30, 2024·1 cites·21 claims
- 1388US9676759B2Isoindolinone inhibitors of phosphatidylinositol 3-kinaseVERTEX PHARMA·Filed 2013·Granted Jun 13, 2017·8 cites·11 claims
- 1487US12180225B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2022·Granted Dec 31, 2024·1 cites·19 claims
- 1586US8354419B2Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2010·Granted Jan 15, 2013·10 cites·23 claims
- 1685US12076405B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Sep 3, 2024·1 cites·20 claims
- 1783US2025057957A1Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1883US2025121069A1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1981US11753397B2Cereblon binders for the degradation of ikarosC4 THERAPEUTICS INC·Filed 2020·Granted Sep 12, 2023·1 cites·19 claims
- 2081US8779156B2Analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Granted Jul 15, 2014·7 cites·27 claims
- 2180US2025127903A1Substituted piperidine degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2277US10118904B2Triazoles for the treatment of Demyelinating DiseasesVERTEX PHARMA·Filed 2016·Granted Nov 6, 2018·3 cites·34 claims
- 2376US12441740B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2024·Granted Oct 14, 2025·0 cites·19 claims
- 2476US10183933B2Isoindolinone inhibitors of phosphatidylinositol 3-kinaseVERTEX PHARMA·Filed 2017·Granted Jan 22, 2019·1 cites·10 claims
- 2569US8765731B2Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Granted Jul 1, 2014·1 cites·22 claims
- 2667US2023082430A1Tricyclic degraders of ikaros and aiolosC4 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2763US2025121070A1Compounds for the targeted degradation of smarca2C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2862US2023190760A1Advantageous therapies for disorders mediated by ikaros or aiolosC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2962US2019076539A1Amine-linked c3-glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3061US12454521B2Targeted protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Oct 28, 2025·0 cites·25 claims
- 3161US2023339902A1Tricyclic ligands for degradation of ikzf2 or ikzf4C4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3260US2023372496A1Tricyclic heterobifunctional compounds for degradation of targeted proteinsC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3358US2025018046A1Compounds for targeting degradation of irak4 proteinsBIOGEN MA INC·Filed 2022·Application pending·0 cites
- 3458US2025302815A1Protein tyrosine phosphatase targeting ligandsCALICO LIFE SCIENCES LLC·Filed 2022·Application pending·0 cites
- 3557US2014243257A1Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2014·Application pending·0 cites
- 3656US2023233692A1Compounds for targeted degradation of retC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3756US2024343733A1Compounds for targeting degradation of irak4 proteinsBIOGEN MA INC·Filed 2022·Application pending·0 cites
- 3855US10766869B2Triazoles for the treatment of demyelinating dieasesVERTEX PHARMA·Filed 2018·Granted Sep 8, 2020·0 cites·34 claims
- 3955US2024391912A1Morphic forms of cft7455 and methods of manufacture thereofC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4053US2024018118A1Tricyclic compounds to degrade neosubstrates for medical therapyC 4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4152US2012040950A1Isoindolinone inhibitors of phosphatidylinositol 3-kinaseARONOV ALEX·Filed 2010·Application pending·0 cites
- 4251US2024383886A1Protein Tyrosine Phosphatase Degraders and Methods of Use ThereofCALICO LIFE SCIENCES LLC·Filed 2020·Application pending·0 cites
- 4343US2013102629A1Analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when James A. Henderson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →